Drug Profile
Research programme: anti-CD20 monoclonal antibodies - InNexus Biotechnology
Alternative Names: DXL 625; DXLr120Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InNexus Biotechnology
- Class Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Canada (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Canada (Parenteral)
- 04 Mar 2011 DXL 625 is available for licensing. www.ixsbio.com